KB-1092

Vobramitamab

Background

The potential antineoplastic drug vobramitamab duocarmazine is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin G1 (IgG1)/kappa monoclonal antibody called vobamitamab that binds to the surface antigen B7-H3. B7-H3 is overexpressed on specific tumor cells and certain immune cells and has a negative regulatory effect on T-cell activation. Once the ADC is internalized by the B7-H3 expressing tumor cells, a cleavable vc linker releases the duocarmycin payload, which binds to the minor groove of DNA and induces cell death by alkylating adenine at the N3 position. B7-H3 expression is correlated with poor prognosis as it plays a significant role in immuno-evasion, tumor cell invasion, and metastasis while being minimally expressed in normal human tissues.

Specifications

Catalog Number:
KB-1092
Cell Line Name:
Vobramitamab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
B7-H3
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1. Anti-tumor activity of vobramitamab duocarmazine (MGC018), an investigational duocarmycin-based anti-BH3 antibody-drug conjugate (ADC), in preclinical neuroblastoma models (AACR 2023)
Please enable JavaScript in your browser to complete this form.